Physician profile
Jim Pang
NPI 1780690230
$13,800.27
in general payments reported to CMS, 2019-2025
34 companies · $2,451 in 2025
The $2,451 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $1,575 · 2021: $1,830 · 2022: $2,249 · 2023: $2,376 · 2024: $1,928 · 2025: $2,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,555 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,555.06 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,993.71 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $1,195.80 | 2019-2025 | Rexulti, Nuedexta |
| Alkermes, INC. | $1,115.82 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $1,074.49 | 2019-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $1,000.82 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $876.27 | 2019-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $867.76 | 2020-2025 | Caplyta |
| Abbvie INC. | $860.29 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $745.29 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $682.08 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Sunovion Pharmaceuticals INC. | $488.64 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $431.54 | 2020-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $431.27 | 2019-2025 | Fanapt, Hetlioz |
| Indivior INC. | $359.47 | 2019-2023 | Perseris |
| Janssen Scientific Affairs, LLC | $200.00 | 2024 | Spravato |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $199.08 | 2021-2025 | Qelbree |
| Allergan, INC. | $163.29 | 2019-2020 | |
| Eisai INC. | $160.96 | 2020-2021 | |
| Harmony Biosciences LLC | $156.90 | 2025 | |
| Brainsway USA INC | $140.86 | 2021 | |
| Shire North American Group INC | $112.93 | 2019 | |
| Corium, LLC | $75.62 | 2022-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $66.92 | 2019-2024 | Jornay Pm |
| Noven Therapeutics, LLC | $55.79 | 2021-2024 | Secuado, Xelstrym |
| Adlon Therapeutics L.P. | $52.61 | 2020-2021 | |
| Acadia Pharmaceuticals INC | $45.33 | 2025 | Nuplazid |
| Idorsia Pharmaceuticals US INC | $44.68 | 2022-2024 | Quviviq |
| Bausch Health US, LLC | $43.40 | 2022-2023 | Aplenzin |
| Scilex Pharmaceuticals INC. | $41.06 | 2019 | |
| Collegium Pharmaceutical, INC. | $36.06 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $30.23 | 2022 | |
| Orexo US, INC. | $19.90 | 2019 | |
| Neuronetics, INC. | $16.83 | 2020 | |
| Tris Pharma INC | $14.57 | 2025 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jim Pang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.